911

SHOULD WE SCREEN MALES AND FEMALES DIFFERENTLY FOR COLORECTAL CANCER? A COST-EFFECTIVENESS ANALYSIS

Date
May 20, 2024
Explore related products in the following collection:

Background
Most colorectal cancer (CRC) screening programs use a uniform screening strategy. However, it may be more efficient to screen males and females differently due to (ambivalent) biological and demographic differences between the sexes. For example, males are known to have higher Hemoglobin concentrations in their stool and a higher prevalence of advanced colorectal neoplasia, leading to a higher positivity rate for fecal immunochemical testing (FIT). At the same time, females have a higher life expectancy than males, which is why they may benefit more from screening at older ages. We investigated the cost-effectiveness of several sex-specific CRC screening strategies.

Methods
The MISCAN-Colon microsimulation model was used to simulate CRC screening for males and females separately while varying four parameters: screening interval (1, 2 or 3 years), FIT positivity cut-off (15, 20, 30, 40, 47, 50 or 60 microgram Hemoglobin per gram feces [µg Hb/g]), starting age (50, 52, 54, 55, 56, 58 or 60 years) and stopping age (70, 72, 74, 75, 76, 78 or 80 years). This resulted in 1029 screening strategies per sex. For each of these strategies, quality-adjusted life-years (QALYs) gained, costs and colonoscopy demand were calculated. Efficient screening strategies, i.e. strategies that provide the best value for money, were identified for a scenario with and without colonoscopy capacity restrictions. We assumed a willingness-to-pay threshold of 20,000 EUR per QALY gained throughout.

Results
When colonoscopy capacity was unlimited, most of the efficient strategies had the lowest FIT cut-off considered, i.e. a cut-off of 15 µg Hb/g, and stopping age 80 (Figure). The cheapest efficient strategies had a screening interval of three years starting at age 60, whereas the costliest strategies had an interval of one year starting at age 50. Screening strategies for males and females were similar. Costs and effects of efficient strategies ranged from 198 QALYs gained and cost-saving to 435 QALYs gained at €603,197 per 1,000 simulated males and 1,000 simulated females combined. The optimal screening strategy comprised annual screening at a FIT positivity cut-off of 15 µg Hb/g for ages 50 through 80 for both sexes. When colonoscopy capacity was restricted to 20% extra capacity compared to what is currently required for the Dutch screening program, efficient strategies had a higher FIT positivity cut-off and stopping age for males compared to females.

Conclusion
From a cost-effectiveness perspective, it is not recommended to stratify CRC screening by sex if colonoscopy capacity is unlimited. However, if the capacity is restricted, more intensive screening at a higher FIT positivity cut-off is recommended for males.

Tracks

Related Products

Thumbnail for MODELING OPTIMAL STOPPING AGES FOR COLORECTAL CANCER SCREENING BASED ON SEX, COMORBIDITY, AND SCREENING HISTORY
MODELING OPTIMAL STOPPING AGES FOR COLORECTAL CANCER SCREENING BASED ON SEX, COMORBIDITY, AND SCREENING HISTORY
Prior studies showed that the benefits, harms, and costs of colorectal cancer (CRC) screening at older ages highly depend on a patient's sex, health, and screening history. However, these studies were not directly informed by stratified data on CRC risk…
Thumbnail for CMS COVERAGE DECISION: IMPLICATIONS FOR COST-EFFECITVENESS OF BLOOD-BASED COLORECTAL CANCER SCREENING
CMS COVERAGE DECISION: IMPLICATIONS FOR COST-EFFECITVENESS OF BLOOD-BASED COLORECTAL CANCER SCREENING
A blood-based colorectal cancer (CRC) screening test may increase screening participation. However, blood-based screening tests may be less effective than current guideline-endorsed options…
Thumbnail for FAECAL IMMUNOCHEMICAL TEST TO DETECT COLORECTAL NEOPLASIA IN LYNCH SYNDROME – A PROSPECTIVE MULTICENTRE STUDY
FAECAL IMMUNOCHEMICAL TEST TO DETECT COLORECTAL NEOPLASIA IN LYNCH SYNDROME – A PROSPECTIVE MULTICENTRE STUDY
Colonoscopy surveillance for Lynch syndrome is burdensome and post-colonoscopy colorectal cancers (CRCs) still occur. The non-invasive faecal immunochemical test (FIT) might guide optimal colonoscopy intervals…
Thumbnail for CHARACTERISTICS OF A COST-EFFECTIVE BLOOD TEST FOR COLORECTAL CANCER SCREENING
CHARACTERISTICS OF A COST-EFFECTIVE BLOOD TEST FOR COLORECTAL CANCER SCREENING
Blood-based biomarker tests have been developed as a non-invasive colorectal cancer (CRC) screening method to triage patients to colonoscopy…